Why Pliant Therapeutics, Inc.’s (PLRX) Stock Is Up 5.22%
As of Monday, May 18, Pliant Therapeutics, Inc.’s PLRX share price has surged by 5.22%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Pliant Therapeutics, Inc.’s (PLRX) Stock Is Down 9.77%
As of Monday, April 20, Pliant Therapeutics, Inc.’s PLRX share price has dipped by 9.77%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Pliant Therapeutics, Inc.’s (PLRX) Stock Is Down 6.03%
As of Friday, March 13, Pliant Therapeutics, Inc.’s PLRX share price has dipped by 6.03%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Pliant Therapeutics, Inc.’s (PLRX) Stock Is Up 5.31%
As of Wednesday, February 18, Pliant Therapeutics, Inc.’s PLRX share price has surged by 5.31%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Pliant Therapeutics, Inc.’s (PLRX) Stock Is Up 5.86%
As of Tuesday, February 17, Pliant Therapeutics, Inc.’s PLRX share price has surged by 5.86%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | PLRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $69.4 | $618.0 | 18% |
|
| Shares Out (Mil) | 61.9 | 44.8 | 52% |
|
| Institutional Ownership | 97.0% | 85.3% | 72% |
|
| Float (Mil) | 55.0 | 47.4 | 49% |
|
| Beta | 1.27 | 0.70 | 75% |
|
| Avg Daily Volume (000s) | 547 | 390 | 59% |
|
| Price Change (52-week) |
(23.8%) | 68.6% | 27% |
|
| Growth | PLRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (29.2%) | (1.6%) | 14% |
|
| EPS (5yr) | (4.5%) | 14.9% | 26 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 23.8% | (14.9%) | 82% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.383) | ($1.462) | ($1.331) | |
| Month Ago EPS | ($0.364) | ($1.410) | ($0.808) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.364) | ($1.417) | ($1.025) | |
| Year/Year Chg | 6.1% | (39.9%) | (55.1%) | |
| Financials | PLRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $291 | na |
|
| Net Income (TTM) (Mil) | ($92) | ($11) | 12% |
|
| EPS (TTM) | ($1.497) | ($0.700) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($71) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($62) | $5 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $27 | $6 | 34% |
|
| Enterprise Value (Q1) (Mil) | ($63) | $450 | 1% |
|
| Valuation | PLRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.47 | 2.78 | 7% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | PLRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.0% | na |
|
| Net Margin | na | (2.3%) | na |
|
| ROA | (37.7%) | (22.4%) | 14% |
|
| ROE | (50.3%) | (20.2%) | 15% |
|
| Liabilities to Assets | 22.6% | 32.2% | 15% |
|
| F-Score | 3 | 3 | 18% |
|
Pliant Therapeutics, Inc. did not pass any screens on 8/20/2026.
